Protocol
Omega-3 EPA/DHA 2 to 4 g/day (general supplementation)
At 2 to 4 g/day of mixed EPA and DHA the large outcome trials were null: STRENGTH (4 g/day, 13,078 high-risk adults) and OMEMI (1.8 g/day, elderly post-infarction patients).
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
This protocol is fish oil at 2 to 4 grams a day for general health. At these doses, two large studies of mixed fish oils found no drop in heart attacks or strokes. A careful review of 86 studies found little or no effect on heart disease or deaths. At doses above about 1 gram a day, the risk of an irregular heartbeat called atrial fibrillation went up.
- What was measured
- Heart attacks, strokes, heart deaths and related hospital stays in adults at high risk of heart disease.
- How big
- About 2 fewer heart events per 1,000 people (12.2% vs 12.0%), a gap so small the trial found no real difference and was stopped early.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 33190147.
- Who it applies to
- Adults on statins at high risk of heart disease, with high triglycerides and low HDL cholesterol; older adults after a heart attack in a second trial.
- Safety
- At doses above about 1 gram a day, the outcome trials found more atrial fibrillation, an irregular heartbeat, and the rise grew with dose.
- Compared with
- Corn oil capsules, used as a dummy pill, on top of usual care including statins.
- Certainty
- Grade C, resting on: Meta-analyses A study that pools the numbers from several trials into one combined estimate. of randomized trials (mixed/modest).
- What would change this grade
- Could rise to B with: Randomized, double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends., placebo-controlled trial of mixed EPA and DHA at 2 to 4 g a day, with a neutral placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received., not corn or mineral oil. Who: Adults at high cardiovascular risk, at least 5,000 per arm. Measured: Heart attack, stroke and cardiovascular death, with atrial fibrillation and bleeding counted. Length: At least 4 years.
- Cost
- No price recorded yet.
- Sources
- 8 studies cited on this record, listed under Sources.
At 2 to 4 g/day of mixed EPA and DHA the large outcome trials were null: STRENGTH (4 g/day, 13,078 high-risk adults) and OMEMI (1.8 g/day, elderly post-infarction patients). REDUCE-IT's 25 percent event reduction was with purified EPA (icosapent ethyl), a different agent, in a trial funded by its maker against a mineral-oil placebo. The one positive trial of mixed omega-3 at 4 g/day, PISCES, was in hemodialysis patients and does not transfer to general supplementation. Doses above 1 g/day carry a dose-related increase in atrial fibrillation in the outcome trials. The Omega-3 Index The share of EPA and DHA among the fatty acids in red blood cell membranes, reported as a percentage. is a blood marker; its 8 percent target comes from observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. data and no trial has treated to it.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on cardiovascular events. At this protocol's dose the large trials of mixed EPA and DHA were null: STRENGTH at 4 g/day (PMID 33190147) and OMEMI at 1.8 g/day (PMID 33191772). The pooled evidence for mixed omega-3 is modest and comes mostly from trials at 1 g/day or less: a Cochrane review of 86 randomized trials found little or no effect on all-cause mortality or cardiovascular events at high certainty and a possible slight reduction in coronary death (Abdelhamid et al., 2020; PMID 32114706), and a 13-trial meta-analysis found lower risk that rose with dose by extrapolation (Hu et al., 2019; PMID 31567003). The one positive trial at 4 g/day of mixed omega-3, PISCES (PMID 41201837), was in hemodialysis patients, a population this general protocol does not cover. Mixed evidence, with the dedicated trials at the dose null, is C.
HARM AT THIS DOSEatrial fibrillation rose in the outcome trials in proportion to dose, hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. 1.49 above 1 g/day (Gencer et al., 2021; PMID 34612056) and odds ratio 1.43 above 1.5 g/day in high-risk patients (Abuknesha et al., 2026; PMID 42517224), with OMEMI itself showing a borderline increase.
WHAT THIS GRADE DOES NOT COVERpurified EPA (icosapent ethyl), the agent in REDUCE-IT (PMID 30415628), a different product funded by its maker, graded separately on the omega-3 record; hemodialysis patients, where PISCES was positive; the Omega-3 Index as a target, which rests on observational data; and any claim that one capsule form (ethyl ester, re-esterified triglyceride, carboxylic acid) outperforms another, which no outcome trial compared.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Trials report an average. This box says whether any trial on this record looked at who the result applies to, and what it found.
For this record's Grade C · Tested in a selected group onlyThe one positive trial of mixed omega-3 at 4 g/day, PISCES (PMID 41201837), enrolled only hemodialysis patients; the large trials at this dose in other groups were null. On harm, Abuknesha et al. (Circ Arrhythm Electrophysiol, 2026; PMID 42517224) found the rise in atrial fibrillation confined to doses above 1.5 g/day in high-risk patients. The result applies to the group the trial enrolled.
Evidence notes: randomized trial, meta-analysis
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Cardiovascular events, including coronary death (hard)
Last reviewed: October 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
At this dose the large trials of mixed EPA and DHA in high-risk adults were null. REDUCE-IT was positive but used purified EPA, a different agent, against a mineral-oil placebo, and PISCES was positive with mixed omega-3 but in hemodialysis patients. A large trial of mixed omega-3 against a neutral placebo is what would settle it.
Why people believe itOne human source; two published case reports of benefit; four reports of harm.
The case for higher-dose omega-3 is that EPA and DHA from fish lower triglycerides by 15 to 30 percent at 2 to 4 g a day, calm inflammation and steady heart rhythm. A large trial of a purified EPA drug at 4 g a day, in people with high triglycerides already on statins, cut cardiovascular events by a quarter, and many take fish oil at that dose on that basis.
What supporters point to, and what each source actually shows. None of it is enough to move this letter higher; the trial described above under Evidence wanted is what would.
- Human trial, a different useIn 8,179 adults with high triglycerides on statins, 4 g a day of icosapent ethyl, a purified EPA drug, cut the main cardiovascular outcome to 17.2 percent from 22.0 percent on mineral oil placebo over about 5 years. A different agent from mixed fish oil, in a trial funded by its maker. PMID 30415628
A case report describes what happened to one or a few patients. It cannot show the treatment caused the change, and reports of success are published more often than reports of failure.
- A 14-year-old boy whose fast heart rhythm had not responded to ablation or drugs became free of it 4 weeks after starting 2 g a day of omega-3. One patient, with no comparison. PMID 31280732
- A report of a patient whose recurrent ventricular tachycardia, a dangerous fast heart rhythm, stopped on omega-3 after drugs had failed. One patient, with no comparison. PMID 16635988
- A report of a fatal bleed after a head injury in a patient taking fish oil together with warfarin, a blood thinner. PMID 28033135
- A 60-year-old amateur athlete getting about 20 g of omega-3 a day from supplements and food for a year developed a bleeding ulcer in the upper small intestine after a course of cortisone and antibiotics. PMID 24281788
- A 54-year-old man developed insomnia, nighttime panic and worse anxiety on a high-EPA fish oil taken for depression. PMID 26634135
- A patient developed vitamin A poisoning after long-term use of high-dose fish oil supplements. PMID 2331929
Searched PubMed, October 2026: 42 case report record(s) returned. 12 describe harm, mostly bleeding, including a fatal brain bleed in a patient also on warfarin, plus warfarin interactions, a rise in LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. cholesterol and vitamin A excess; four are listed. 21 describe improvement, in heart rhythm, skin, lipid and psychiatric conditions, many alongside other treatment; two are listed. One is a dog, and eight are population surveys, reviews and hypothesis papers.
Animal and laboratory workTwo studies in animals or cells. Not counted toward the letter.
None of this is human evidence and none of it counts toward the letter. It is listed so the reader can see what the idea rests on. Most findings in animals do not hold up when tested in people.
- DogIn dogs with a healed heart attack, blocking a heart artery during exercise reliably caused fatal heart rhythm. Infusions of pure EPA, DHA or alpha-linolenic acid protected 5 of 7, 6 of 8 and 6 of 8 dogs from that rhythm. PMID 10318669 The fatty acids were infused into a vein, not taken by mouth.
- DogOf 76 dogs with a healed heart attack, 50 got 1 to 4 g a day of EPA and DHA by mouth for 3 months and 26 got corn oil. Heart levels rose, but treatment did not protect susceptible dogs from fatal rhythm during an artery blockage test better than placebo, and caused rhythm problems in a third of resistant dogs. PMID 22333345
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Omega-3 among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Dose, form and timing
Triglycerides at baseline and 3 months: a 15 to 30 percent reduction is the most consistent randomized effect of 2 to 4 g/day of EPA plus DHA, and it did not translate into fewer events in the dedicated trials. The Omega-3 Index can be measured, but its 8 to 12 percent zone is an observational association with cardiovascular risk, not a threshold any trial treated to. Doses are stated as actual EPA plus DHA content, not total fish oil weight. New palpitations or an irregular pulse at this dose warrant a rhythm check, given the dose-related atrial fibrillation signal.
Safety
Cautions documented in human studies. Each caution on this record, sorted by what it rests on.
- Atrial fibrillation: outcome trials found more atrial fibrillation at doses above about 1 g/day, and the rise grew with dose (PMID 34612056 PMID 42517224)
- 4 published case reports of harm, described in the record's reports of harm (PMID 28033135 PMID 24281788 PMID 26634135 PMID 2331929)
None recorded.
None recorded.
Does not apply: human harm data are listed above.
Grade history
How this letter has changedLatest: No. 243 · October 2026 · Corrected.
The description led with REDUCE-IT's 25 percent reduction (Bhatt et al., NEJM, 2019; PMID 30415628), which tested purified EPA, a different agent, in a trial funded by its maker against a mineral-oil placebo; it now leads with the null trials at the protocol's dose, STRENGTH (Nicholls et al., JAMA, 2020; PMID 33190147) and OMEMI (Kalstad et al., Circulation, 2021; PMID 33191772). Added: the dose-related atrial fibrillation increase in the outcome trials (Gencer et al., 2021; PMID 34612056; Abuknesha et al., 2026; PMID 42517224), the most relevant harm at 2 to 4 g/day, and OMEMI's own borderline signal; the Cochrane review's high-certainty nulls on mortality and cardiovascular events (PMID 32114706) beside the slight coronary death reduction the record quoted; the population-specific positive PISCES trial in hemodialysis (Lok et al., NEJM, 2026; PMID 41201837); and the fact that Hu 2019 (PMID 31567003) pooled trials mostly at 1 g/day or less. The Omega-3 Index target and the form line are restated as untested. The not-replicated flag, inconsistent with the record, is removed, and the name loses its dash. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 30415628 PMID 31567003 PMID 32114706 PMID 33190147 PMID 33191772 PMID 34612056 PMID 41201837 PMID 42517224
The general 2 to 4 g/day omega-3 protocol held a B on pooled analyses mostly at 1 g/day or less and on REDUCE-IT, which tested purified EPA. At this dose of mixed EPA and DHA the large trials were null: STRENGTH (Nicholls et al., JAMA 2020; PMID 33190147) and OMEMI (Kalstad et al., Circulation 2021; PMID 33191772). C. Editor adjudication, October 2026.PMID 33190147 PMID 33191772
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- October 2026. By the EBL editor, Arnold Sandlow, DC.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullEight papers, each linked to its PubMed record.
Hu et al. (Journal of the American Heart Association, 2019; PMID 31567003): meta-analysis of 13 trials, 127,477 participants; marine omega-3 associated with lower myocardial infarction, coronary death and total cardiovascular disease, with a dose-response in meta-regression; the pooled trials were mostly at 1 g/day or less, so the dose-response is an extrapolation and does not test 2 to 4 g/day. Abdelhamid et al. (Cochrane Database of Systematic Reviews A review that searches for every study on a question using a method set in advance, then assesses them together., 2020; PMID 32114706): 86 trials, 162,796 participants; little or no effect on all-cause mortality (RR 0.97, high certainty), cardiovascular events (RR 0.96, high certainty), stroke or arrhythmia; coronary death may be slightly lower (RR 0.90, low to moderate certainty). Nicholls et al. (JAMA, 2020; PMID 33190147), STRENGTH: 13,078 statin-treated high-risk adults, 4 g/day of a carboxylic acid EPA plus DHA formulation against corn oil, stopped early for futility; primary events 12.0 against 12.2 percent (hazard ratio 0.99), more gastrointestinal adverse events. Kalstad et al. (Circulation, 2021; PMID 33191772), OMEMI: 1,027 patients aged 70 to 82 after myocardial infarction, 1.8 g/day for 2 years; primary events 21.4 against 20.0 percent (hazard ratio 1.08), new atrial fibrillation 7.2 against 4.0 percent (hazard ratio 1.84, p=0.06). Lok et al. (NEJM, 2026; PMID 41201837), PISCES: 1,228 hemodialysis patients, 4 g/day of fish oil (1.6 g EPA, 0.8 g DHA) against corn oil for 3.5 years, publicly funded; serious cardiovascular events lower (hazard ratio 0.57), a clinical population that does not transfer to general supplementation. Bhatt et al., REDUCE-IT (New England Journal of Medicine, 2019; PMID 30415628): 8,179 statin-treated patients, 4 g/day icosapent ethyl, purified EPA ethyl ester; primary events 17.2 against 22.0 percent; funded by Amarin, the drug's maker, with a mineral-oil placebo whose inertness has been questioned; a different agent, graded separately at B on the omega-3 record. Atrial fibrillation: Gencer et al. (Circulation, 2021; PMID 34612056), 7 cardiovascular outcome trials, 81,210 patients; hazard ratio 1.25 overall and 1.49 in trials above 1 g/day, rising 1.11 per gram. Abuknesha et al. (Circ Arrhythm Electrophysiol, 2026; PMID 42517224), 35 trials, 114,592 people; the increase confined to doses above 1.5 g/day in high-risk patients (odds ratio 1.43, absolute risk The actual chance of an event in a group. A fall from 2 percent to 1 percent is a 1-point absolute reduction, even though it is a 50 percent relative one. 0.8 percent), with authors who hold interests in an omega-3 seller and a fatty acid testing laboratory. General supplementation benefit, where the pooled analyses find it, is modest and sits mostly at doses of 1 g/day or less; at this protocol's dose the large mixed EPA and DHA trials were null.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("omega-3"[tiab] OR "n-3 fatty acid*"[tiab] OR "fish oil"[tiab]) AND (cardiovascular events[tiab] OR "major adverse cardiovascular"[tiab]) AND ("4 g"[tiab] OR "2 g"[tiab] OR "1.8 g"[tiab] OR high-dose[tiab]) AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since October 2026.
Last run October 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →